[CLSTR]
< Back to situations

Monitor this situation.

[SITUATION] · [ACTIVE] · [BUSINESS]

2 clusters · 6 sources · 20 days · First seen · Last updated

Ocugen clinical trial results and market performance

Overview

Ocugen experienced significant market volatility following an interim analysis of its OCU410ST gene therapy study for Stargardt disease. Data from the first 26 participants indicated a “negative treatment effect,” causing the company’s stock to drop approximately 21 percent within a week. Despite these results, an independent data monitoring committee recommended continuing the study for another eight months, noting the current data set was insufficient for a definitive conclusion.

By late September, analysts at HC Wainwright raised their FY2026 earnings estimates for Ocugen, forecasting earnings of ($0.27) per share, an improvement from the previous ($0.28) forecast.

Entities

Ocugen, Inc. · Oculis Holding AG · HC Wainwright · Lionel Carnot · Ocugen

Timeline

  1. [BUSINESS] 3 sources
    Ocugen earnings estimates raised as Oculis board member resigns

    HC Wainwright raised FY2026 earnings estimates for Ocugen, Inc., while Oculis Holding AG announced the resignation of board director Lionel Carnot.

  2. [BUSINESS] 4 sources
    Ocugen stock drops following negative interim Stargardt disease trial data

    Ocugen's stock fell 21% following an interim analysis of its Stargardt disease gene therapy study showing a negative treatment effect, though the clinical trial will continue for eight more months.

Sources

ad-hoc-news.de · it-boltwise.de · marketwire.com · newsable.asianetnews.com · seekingalpha.com · stocknews.com